Q-omics provides the consensus-scored BCL3 profile across patient tissues and cancer cell-line models. BCL3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BCL3 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, BCL3 protein abundance shows 26,701 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, KICH, and LUAD as cancer lineages where BCL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL3 survival associations across molecular data types. BCL3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL3 RNA expression–survival associations across cancer types. High BCL3 expression shows unfavorable associations in KIRC, UVM, UCS and LGG, but favorable associations in HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BCL3 RNA expression.
This table summarizes BCL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for BCL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL3 shows lower tumor expression in KICH and BLCA and higher tumor expression in KIRC, THCA, BRCA and STAD. The KICH box plot shows higher BCL3 RNA expression in normal versus tumor tissue (log2 FC = −2.127, t-test p < 0.001).
This table shows molecular features associated with BCL3 in patient tissues and cancer cell lines. In patient samples, BCL3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
